Repligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $94.1 million with strong margin expansion
Overall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $ 348 -$ 352 million and overall revenue growth to 29%-30% for full year 2020, representing 23 %- 24 % organic growth Completes acquisition of Non-Metallic Solutions and an nounces a greement to a cquire b ioprocess s ystems i nnovator ARTeSYN Biosolutions WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2020. Provided in this press release are financial highlights for the three- and nine- month periods ended September 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our momentum